Abstract
Oral immunotherapy (OIT) treatment for peanut allergy is now FDA approved for treatment of peanut allergic patients. The need for accurate and robust prognostic biomarkers to aid in patient selection is critical. We investigated the long-term safety of peanut OIT from our POISED study, and the potential role of BATs in predicting adverse events during long-term OIT and double-blind-placebo-controlled-food challenges (DBPCFCs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
